title: CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
abstract: Angiogenesis plays an important role in cancer progression in many types of cancer. Evaluation of angiogenesis is often performed, but the optimal methodology for human cancer has not been agreed upon. As adequate evaluation of angiogenesis in cancer tissues might be important for prediction of prognosis and treatment decisions, we evaluated angiogenesis semiquantitatively by assessing microvessel density (MVD) in urothelial cancer of the upper urinary tract (UC-UUT). We compared the performance of three endothelial cell markers (CD31, CD34, and CD105) on formalin-fixed tissues from 122 patients diagnosed with UC-UUT without metastasis. Vascular endothelial growth factor (VEGF)-A expression was also evaluated immunohistochemically. Correlations between MVD with each marker and pT stage, grade, survival, and VEGF-A expression were investigated. Mean (standard deviation) MVD as estimated by immunohistochemical staining with anti-CD31, anti-CD34, and anti-CD105 were 47.1 (17.9)/high-power field (HPF), 70.9 (19.5)/HPF, and 31.2 (16.7)/HPF, respectively. Although all MVDs were significantly associated with pT stage and grade, CD105-MVD showed the strongest association. Similarly, CD105-MVD showed the strongest correlation with VEGF-A expression (r = 0.530, p < 0.001). Although all MVDs were associated with metastasis-free survival and cause-specific survival on univariate analysis, only CD105-MVD was retained as an independent predictor in multivariate analysis including pT stage and grade. CD105-MVD may be the preferred marker for semiquantitative assessment of angiogenesis in patients with UC-UUT.
authors: Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan, int.doc.miya@m3.dion.ne.jp.
authors: Yasuyoshi
authors: Y
authors: Miyata
authors: Yuji
authors: Y
authors: Sagara
authors: Shin-ichi
authors: S
authors: Watanabe
authors: Akihiro
authors: A
authors: Asai
authors: Tomohiro
authors: T
authors: Matsuo
authors: Kojiro
authors: K
authors: Ohba
authors: Tomayoshi
authors: T
authors: Hayashi
authors: Hideki
authors: H
authors: Sakai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism*; D018952:Antigens, CD34 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis; D000071063:Endoglin; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000378:metabolism*; D014551:Urinary Tract / Q000378:metabolism* / Q000473:pathology; D014571:Urologic Neoplasms / Q000098:blood supply / Q000175:diagnosis / Q000378:metabolism*; D019459:Urothelium / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011956:Receptors, Cell Surface; D042461:Vascular Endothelial Growth Factor A
references: Clin Cancer Res. 2002 Jun;8(6):1863-70
references: 12060629
references: N Engl J Med. 1991 Jan 3;324(1):1-8
references: 1701519
references: J Clin Pathol. 2004 Jun;57(6):591-7
references: 15166262
references: Neuropathology. 2005 Sep;25(3):201-6
references: 16193836
references: Eur J Gynaecol Oncol. 2009;30(3):285-8
references: 19697622
references: Int Urol Nephrol. 2010 Mar;42(1):103-7
references: 19484376
references: Oral Oncol. 2005 Feb;41(2):147-55
references: 15695116
references: N Engl J Med. 1996 Apr 4;334(14):920-1; author reply 921
references: 8596586
references: BJU Int. 2003 Sep;92(4):389-92
references: 12930427
references: Oncol Rep. 2007 Jul;18(1):133-8
references: 17549358
references: Gynecol Oncol. 2009 Mar;112(3):583-9
references: 19110305
references: Urology. 2008 Apr;71(4):749-54
references: 18295862
references: Urol Oncol. 2004 Jan-Feb;22(1):1-6
references: 14969795
references: Oncogene. 2003 Sep 29;22(42):6557-63
references: 14528280
references: World J Gastroenterol. 2003 Dec;9(12):2866-9
references: 14669355
references: Anticancer Res. 1998 Sep-Oct;18(5A):3621-8
references: 9858949
references: Ann Clin Lab Sci. 2007 Winter;37(1):39-48
references: 17311868
references: Gynecol Oncol. 2006 Dec;103(3):1007-11
references: 16854456
references: Prog Urol. 2001 Jun;11(3):417-27
references: 11512452
references: Clin Cancer Res. 2001 Nov;7(11):3410-5
references: 11705856
references: J Clin Oncol. 2001 Feb 1;19(3):666-75
references: 11157016
references: J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
references: 1688381
references: J Urol. 2010 May;183(5):1744-50
references: 20299037
references: Cancer Res. 1999 Feb 15;59(4):856-61
references: 10029075
references: Obstet Gynecol. 2000 Aug;96(2):224-8
references: 10908767
references: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):800-6
references: 16467091
references: Am J Clin Pathol. 1991 Jul;96(1):25-31
references: 1712541
references: Eur Urol. 2004 Jun;45(6):737-43
references: 15149745
references: Gynecol Oncol. 2009 Mar;112(3):469-74
references: 19135712
references: Clin Cancer Res. 2003 May;9(5):1734-40
references: 12738728